Interleukin-6 promoter polymorphism at position -174 in giant cell arteritis

Journal of Rheumatology

Volumn 32, Issue 11, 2005, Pages 2173-2177

  Salvarani, Carlo ^a,d   Casali, Bruno ^b   Farnetti, Enrico ^b   Pipitone, Nicolò ^a   Nicoli, Davide ^b   Macchioni, Pierluigi ^a   Cimino, Luca ^c   Bajocchi, Gianluigi ^a   Catanoso, Maria Grazia ^a   Boiardi, Luigi ^a  

^a Unità Operativa Complessa di Medicina Trasfusionale   (Italy)

^b Laboratorio di Biologia Molecolare   (Italy)

^c Unità Operativa di Chirurgia Oculistica   (Italy)

^d S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Giant cell arteritis; Interleukin 6 polymorphism; Ischemic complications; Polymyalgia rheumatica

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; DNA; INTERLEUKIN 6; PREDNISONE;

ACUTE PHASE RESPONSE; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; GIANT CELL ARTERITIS; HUMAN; INFLAMMATION; ITALY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RHEUMATIC POLYMYALGIA;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-6; ITALY; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMYALGIA RHEUMATICA; PROMOTER REGIONS (GENETICS); TEMPORAL ARTERITIS;

EID: 27744518363     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-71.
2. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003;349:160-9.
3. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002;13:357-68.
4. Corrigall VM, Dolan AL, Dasgupta B, Panayi GS. The sequential analysis of T lymphocyte subsets and interleukin-6 in polymyalgia rheumatica patients as predictors of disease remission and steroid withdrawal. Br J Rheumatol 1997;36:976-80.
5. Dasgupta B, Panayi GS. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1990;29:456-8.
6. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum 1993;36:1286-94.
7. Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000;43:1041-8.
8. Weyand CM, Fulbright JW, Evans JM, Hunder GG, Goronzy JJ. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 1999;159:577-84.
9. Salvarani C, Cantini F, Niccoli L, et al. Acute-phase response reactants and the risk of developing relapse/recurrence in polymyalgia rheumatica: a prospective follow up study. Arthritis Rheum 2005;53:33-8.
10. Cid MC, Font C, Oristrell J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998;41:26-32.
11. Gonzalez-Gay MA, Blanco R, Rodriguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998;41:1497-504.
12. Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 2001;111:211-7.
13. Nesher G, Berkun Y, Mates M, et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine 2004;83:114-22.
14. Salvarani C, Cimino L, Macchioni PL, et al. Risk factors for visual loss in an Italian population based cohort of patients with giant cell arteritis. Arthritis Rheum 2005;53:293-7.
15. Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003;107:2428-34.
16. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-76.
17. Gonzalez-Gay MA, Boiardi L, Garcia-Porrua C, Macchioni P, Amor-Dorado JC, Salvarani C. Geographical and genetic factors do not account for significant differences in the clinical spectrum of giant cell arteritis in southern europe. J Rheumatol 2004;31:520-3.
18. Salvarani C, Macchioni PL, Tartoni PL, et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol 1987;5:205-15.
19. Licastro F, Grimaldi LM, Bonafe M, et al. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol Aging 2003;24:921-6.
20. Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 2001;22:2243-52.
21. Jenny NS, Tracy RP, Ogg MS, et al. In the elderly, interleukin-6 plasma levels and the -174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vase Biol 2002;22:2066-71.
22. Flex A, Gaetani E, Pola R, et al. The -174 G/C polymorphism of the interleukin-6 gene promoter is associated with peripheral artery occlusive disease. Eur J Vase Endovasc Surg 2002;24:264-8.
23. DeMichele A, Martin AM, Mick R, et al. Interleukin-6 - 174G→C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 2003;63:8051-6.
24. Vozarova B, Fernandez-Real JM, Knowler WC, et al. The interleukin-6 (-174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet 2003;112:409-13.
25. Ferrari SL, Garnero P, Emond S, Montgomery H, Humphries SE, Greenspan SL. A functional polymorphic variant in the interleukin-6 gene promoter associated with low bone resorption in postmenopausal women. Arthritis Rheum 2001;44:196-201.
26. Schluter B, Raufhake C, Erren M, et al. Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 2002;30:32-7.
27. Gonzalez-Gay MA, Hajeer AH, Dababneh A, et al. IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. Clin ExpRheumatol 2002;20:179-84.
28. Boiardi L, Casali B, Farnetti E, et al. Relationship between interleukin-6 promoter polymorphism at position -174, interleukin-6 serum levels and the risk of developing relapse/recurrence in polymyalgia rheumatica [abstract]. Arthritis Rheum 2004; Suppl 50:S434.
29. Kelberman D, Hawe E, Luong LA, et al. HIFMECH study group. Effect of interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe. The HIFMECH Study. Thromb Haemost 2004;92:1122-8.
30. Dababneh A, Gonzalez-Gay MA, Garcia-Porrua C, Hajeer A, Thomson W, Ollier W. Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol 1998;25:2140-5.
31. Salvarani C, Boiardi L, Mantovani V, et al. HLA-DRBl, DQA1, and DQB1 alleles associated with giant cell arteritis in northern Italy. J Rheumatol 1999;26:2395-9.
32. Salvarani C, Casali B, Boiardi L, et al. Intercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica/giant cell arteritis: association with disease risk and severity. J Rheumatol 2000;27:1215-21.
33. Amoli MM, Shelley E, Mattey DL, et al. Lack of association between intercellular adhesion molecule-1 gene polymorphisms and giant cell arteritis. J Rheumatol 2001;28:1600-4.
34. Jones KG, Brull DJ, Brown LC, et al. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001;103:2260-5.
35. Brull DJ, Montgomery HE, Sanders J, et al. Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vase Biol 2001;21:1458-63.